Related Experiment Video
Updated: Jun 27, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.5K
Systematic Review of Available CAR-T Cell Trials around the World.
Luciana Rodrigues Carvalho Barros1, Samuel Campanelli Freitas Couto2,3, Daniela da Silva Santurio4
1Center for Translational Research in Oncology, Instituto do Câncer do Estado de Sao Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo 01246-000, Brazil.
Cancers
|June 10, 2022
Summary
CAR-T cell therapies are advancing rapidly, targeting both blood cancers and solid tumors. Future research needs better data tracking for CAR-T clinical trials to clarify treatment strategies.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Chimeric Antigen Receptor T-cell (CAR-T) therapy shows promise for malignancies.
- Clinical trials are expanding globally, particularly in China and the USA.
Purpose of the Study:
- To review the current landscape and future outlook of CAR-T cell therapies.
- To identify key targets and evolving CAR construct generations.
- To assess combination strategies and data gaps in CAR-T clinical trials.
Main Methods:
- Systematic review of CAR-T cell therapy clinical studies.
- Analysis of targeted antigens, CAR construct generations, and combination therapies.
- Evaluation of data availability on product formulation and administration.
Main Results:
- CD19 and BCMA are primary targets for hematological malignancies; solid tumors target mesothelin, GPC3, CEA, MUC1, HER2, and EGFR.
- Second-generation CAR constructs dominate, with increasing exploration of third and fourth generations.
- Combination therapies with immune checkpoint inhibitors are under investigation.
- Scarcity of data on cell formulation and administration parameters was noted.
Conclusions:
- CAR-T therapy is a rapidly evolving field with significant global research activity.
- Further standardization and data transparency in clinical trials are crucial for advancing CAR-T treatments.
- Improved data accessibility on ClinicalTrials.gov is recommended for a clearer overview.
